As expected, the FDA hit Avanir Pharmaceuticals Inc. late Wednesday with a complete response letter (CRL) related to the new drug application (NDA) for AVP-825, a drug-device combination product consisting of low-dose sumatriptan powder, delivered intranasally with a breath-powered delivery technology for the acute treatment of migraine.